Revagenix Appoints Biotechnology Veteran J. Kevin Judice, Ph.D. To Board Of Directors As Andrew McCandlish, Ph.D., Founder And COO, Steps Down From Board

Revagenix, Inc., a biopharmaceutical company focused on the discovery and development of innovative antibiotics, has announced the appointment of J. Kevin Judice, Ph.D., to its board of directors. At the same time, Andrew McCandlish, Ph.D., the company’s founder and chief operating officer, has stepped down from his position on the board. 

Dr. Judice brings a strong scientific background and significant experience in biotechnology leadership to the board of Revagenix. His expertise is expected to provide valuable guidance as the company advances its mission to develop novel antibiotic therapies addressing critical unmet medical needs.

Ryan Cirz, PhD, Chief Executive Officer and Director of Revagenix, stated, “Kevin brings with him a wealth of experience in drug development and successful exits. His early experience in the antimicrobial space, including leading the discovery of telavancin and helming Achaogen through its formative years with the foresight to focus on what became the Gram-negative resistance crisis are critical elements to understanding our mission.  Just as importantly, his later successes outside of the antibacterial space, most notably at DICE Therapeutics, equip him with the perspective needed to ensure Revagenix delivers both on the science and the business of bringing meaningful cures to patients in an incredibly challenging environment.”

Dr. Cirz, stated, “Andy, along with the other founders, has served the Revagenix Board exceptionally well as we gradually built our internal leadership team and searched for additional Directors that could help us achieve our long-term vision. Dr. McCandlish continues in his same critical capacity within the business, and his board resignation simply reflects our success in finding the next key addition to our Board.”  

Tina Marriott, Chair of the Revagenix Board of Directors, also added, “We are thrilled to welcome Kevin to the Board. As a successful founder, CEO, and scientific leader, he brings invaluable experience translating cutting-edge research into medicines that matter—expertise that will be instrumental as we advance our multiple therapeutic candidates into the clinic.”

Dr. Judice mentioned, “The need for novel antibiotics has never been greater, and Revagenix is taking a disciplined and innovative approach to advancing next-generation antimicrobial agents that address unmet medical needs in commercially attractive settings. I look forward to contributing my experience to support the team as it works to deliver transformative therapies for patients facing multidrug-resistant infections.”

Alongside this appointment, Revagenix continues to be supported by an experienced executive team. In addition to Dr. McCandlish, who serves as chief operating officer, the leadership group includes Mick Hurrey, Ph.D., vice president of pharmaceutical development, and Daniel Cloutier, Pharm.D., vice president of development. Together, this team is positioned to drive the company’s ongoing efforts to advance its pipeline of next-generation antibiotics.